BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
April 19, 2022 07:05 ET
|
BioXcel Therapeutics
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth...
BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority
April 19, 2022 07:00 ET
|
BioXcel Therapeutics
Investment will support upcoming U.S. commercial launch activities of IGALMI™ and further clinical pipeline development Extends Company’s cash runway into 2025 NEW HAVEN, Conn., April 19, 2022 ...
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
April 06, 2022 07:00 ET
|
BioXcel Therapeutics
First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder1 IGALMI demonstrated onset of...
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
March 10, 2022 07:05 ET
|
BioXcel Therapeutics
Ready to launch BXCL501 upon approval as Company nears April 5, 2022 PDUFA action date Initiated TRANQUILITY II AND III pivotal Phase 3 trials for BXCL501 in acute treatment of agitation associated...
BioXcel Therapeutics to Present at the Barclays Global Healthcare Conference
March 09, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
February 24, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders
February 22, 2022 11:05 ET
|
BioXcel Therapeutics
BXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo BXCL501 PDUFA Date is April 5, 2022 for...
BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium
February 14, 2022 17:00 ET
|
BioXcel Therapeutics
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts Company plans to continue evaluation of BXCL701 combination as...
BioXcel Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 09, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer
January 19, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...